Kandice Kottke-Marchant



Director, Hemostasis and Thrombosis Laboratory Clinical Pathology, CCF
Phone: (216) 444-2484
Fax: (216) 445-9444
e-mail: marchak@ccsmtp.ccf.org

Education
1979, B.S. Biomedical Engineering, Northwestem University, Evanston, IL.
1985, Ph.D. Macromolecular Science, Case Westem Reserve University.
1986, M.D. Case Westem Reserve University.

Research Interests
Our research is focused on the elucidation of the effect of polymeric substrate interfacial properties on the growth and coagulant function of endothelial cells under flow conditions. To accomplish this, we have developed two flow systems, both a rotating disc and parallel plate system. We specifically study plasminogen activator production, plasminogen activator inhibitor-1 (PAI-1) production, von Willebrand's factor production, tissue factor activity, prostacyclin production, and expression of adhesion proteins by human endothelial cells on biomaterial surfaces under flow conditions. We are also interested in the interaction of the hemostatic system with biomaterials to address the problem of surface-induced thrombogenicity. To investigate this, we are studying the functionality of platelets and proteins (von Willebrand's factor, fibrinogen, fibronectin) adsorbed onto biomaterials sur faces by biochemical assays and quantifying antibody binding to the adsorbed species by nano-scale atomic force microscopy. On a collaborative basis, we are interested in investigating the in vivo hemostatic effects of new cardiovascular devices and antithrombotic and antiplatelet drugs, such as hirudin, Iloprost, tick anticoagu lant peptide, Integrelin and other glycoprotein IIb/IIIa antagonists. These studies involve platelet flow cytometry, platelet aggregation, and assays of coagulation activation products, such as fibrinopeptide A (FpA), prothrombin F1.2, and thrombin-antithrombin complexes.

Selected Publications

  1. Kottke-Marchant, K., Marchant, R.E., Coagulant function of human aortic endothelial cells cultured on plasma polymerized interface materials, J. Biomed. Mater. Res., In Press, 1995.
  2. Wang, I-W, Kottke-Marchant, K., Vargo, R.L., McCarthy, P.M., Hemostatic profiles of 19 HeartMate ventricular assist device recipients," Trans. ASAIO, In Press 1995.
  3. Pasha, R., Benavides, M., Kottke-Marchant, K., Harasaki, H., Reduced expression of platelet surface glycoprotein receptor IIb/IIIa at hyperthermic temperatures; Lab. Investig, In Press 1995.
  4. McCarthy, P.M., Nakatani, S., Vargo, R., Kottke-Marchant, K., Harasaki, H., James, K.B., Savage, R.M., Thomas, J.D., Structural and left ventricular histologic changes after implantable LVAD insertion, Ann Thorac. Surg., 59, 609-613(1995).
  5. Tcheng, J.E., Harrington, R.A., Kottke-Marchant, K., Kleiman, N.S., Ellis, S.G., Kereiakes, D.J., Mick, M.J.,Navetta, F.I., Smith, J.E., Worley, S.J., Miller, J.A., Joseph, D.M., Sigmon, K.N., Kitt, M.M., du Mee, C.P., Califf, R.M., Topol, E.J.; Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention, Circulation, 91, 2151-2157 (1995).

     

    Back to the CCB Homepage!


    Eric Han-Ting Huang
    Center for Cardiovascular Biomaterials
    Copyright 1996
    Last revised: